Details of the Drug
General Information of Drug (ID: DMASO86)
| Drug Name |
4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
CHEMBL1086903; 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide; MLS000532882; AC1LQXAP; CBMicro_028883; Oprea1_410069; Oprea1_118265; MolPort-001-490-660; HMS2484B06; STK413461; ZINC13468414; BDBM50312579; AKOS003253125; MCULE-2070823146; SMR000140320; BIM-0028795.P001; ST50914634; N-cyclohexyl-4-(diphenylmethyl)piperazine-1-carboxamide; N-cyclohexyl-4-(diphenylmethyl)-1-piperazinecarboxamide
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 377.5 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.4 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||


